Error‐prone DNA repair pathways as determinants of immunotherapy activity: an emerging scenario for cancer treatment-Reference-Cited by-同舟云学术

Error‐prone DNA repair pathways as determinants of immunotherapy activity: an emerging scenario for cancer treatment

Published:2020-06 Issue:10 Volume:147 Page:2658-2668
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Caracciolo Daniele¹^ORCID,Riillo Caterina¹,Arbitrio Mariamena²,Di Martino Maria Teresa¹,Tagliaferri Pierosandro¹,Tassone Pierfrancesco¹³

Affiliation:

1. Department of Experimental and Clinical Medicine Magna Græcia University Catanzaro Italy

2. CNR‐Institute for Biomedical Research and Innovation Catanzaro Italy

3. Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology College of Science and Technology, Temple University Philadelphia Pennsylvania USA

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.33038

Reference118 articles.

1. Repair of Endogenous DNA Damage

2. DNA Damage, Aging, and Cancer

3. Endogenous DNA Damage as a Source of Genomic Instability in Cancer

4. DNA damage-induced cell death: lessons from the central nervous system

5. Mechanisms of DNA damage, repair, and mutagenesis

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Deep learning for dual detection of microsatellite instability and POLE mutations in colorectal cancer histopathology;npj Precision Oncology;2024-05-23

2. Unlocking the potential of T‐cell metabolism reprogramming: Advancing single‐cell approaches for precision immunotherapy in tumour immunity;Clinical and Translational Medicine;2024-03

3. Systematic investigation of the homology sequences around the human fusion gene breakpoints in pan-cancer – bioinformatics study for a potential link to MMEJ;Briefings in Bioinformatics;2023-08-26

4. A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer;Journal of Translational Medicine;2023-05-04

5. 2-Hydroxy-3-methylanthraquinone inhibits homologous recombination repair in osteosarcoma through the MYC-CHK1-RAD51 axis;Molecular Medicine;2023-01-30